

**(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE**

(11) Application No. AU 2009331526 B2

(54) Title
Polyunsaturated fatty acid and diol ester as an anti-acne agent

(51) International Patent Classification(s)
C07C 69/587 (2006.01) **A61P 17/08** (2006.01)
A61K 8/37 (2006.01) **A61P 17/10** (2006.01)
A61K 31/22 (2006.01) **A61Q 9/00** (2006.01)

(21) Application No: **2009331526** (22) Date of Filing: **2009.12.21**

(87) WIPO No: **WO10/072738**

(30) Priority Data

(31) Number
0858967 (32) Date
2008.12.22 (33) Country
FR

(43) Publication Date: **2010.07.01**
(44) Accepted Journal Date: **2013.10.24**

(71) Applicant(s)
Pierre Fabre Dermo-Cosmetique

(72) Inventor(s)
Redoules, Daniel;Daunes-Marion, Sylvie;Aries, Marie-Francoise

(74) Agent / Attorney
Phillips Ormonde Fitzpatrick, 367 Collins Street, Melbourne, VIC, 3000

(56) Related Art
WO 1998/013330 A1

(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION EN MATIÈRE DE BREVETS (PCT)

(19) Organisation Mondiale de la Propriété Intellectuelle
Bureau international



(43) Date de la publication internationale
1 juillet 2010 (01.07.2010)

PCT

(10) Numéro de publication internationale

WO 2010/072738 A1

(51) Classification internationale des brevets :
C07C 69/587 (2006.01) *A61K 31/22* (2006.01)
A61K 8/37 (2006.01) *A61P 17/10* (2006.01)
A61Q 9/00 (2006.01) *A61P 17/08* (2006.01)

(81) États désignés (sauf indication contraire, pour tout titre de protection nationale disponible) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(21) Numéro de la demande internationale :
PCT/EP2009/067701

(22) Date de dépôt international :
21 décembre 2009 (21.12.2009)

(25) Langue de dépôt : français

(26) Langue de publication : français

(30) Données relatives à la priorité :
0858967 22 décembre 2008 (22.12.2008) FR

(71) Déposant (pour tous les États désignés sauf US) :
PIERRE FABRE DERMOCOSMÉTIQUE [FR/FR];
45, place Abel Gance, F-92100 Boulogne-Billancourt (FR).

(72) Inventeurs; et

(75) Inventeurs/Déposants (pour US seulement) :
REDOULES, Daniel [FR/FR]; 42, avenue Etienne Billières, F-31300 Toulouse (FR). DAUNES-MARION, Sylvie [FR/FR]; 2, allée du Niger - Résidence Giacomo Bât. B - Appart.1066, F-31000 Toulouse (FR). ARIES, Marie-Françoise [FR/FR]; 13, rue du Grand Sud, F-31750 Escalquens (FR).

(74) Mandataire : AHNER Francis; Cabinet Reginbeau, 20, rue de Chazelles, F-75847 Paris Cedex 17 (FR).

(84) États désignés (sauf indication contraire, pour tout titre de protection régionale disponible) : ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), eurasien (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), européen (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Déclarations en vertu de la règle 4.17 :


— relative à la qualité d'inventeur (règle 4.17.iv))

Publiée :

— avec rapport de recherche internationale (Art. 21(3))

(54) Title : POLYUNSATURATED FATTY ACID AND DIOL ESTER AS AN ANTI-ACNE AGENT

(54) Titre : ESTER DE DIOL ET D'ACIDE GRAS POLYINSATURÉ COMME AGENT ANTI-ACNE



(57) Abstract : The present invention relates to compounds of the following formula (I): where n is an integer between 1 and 15, m is 0, 1, 2 or 3, and R is the hydrocarbon chain of a polyunsaturated fatty acid selected from among omega 3 and omega 6, as well as to pharmaceutical or cosmetic compositions containing same, to a method for preparing and using same, in particular for treating acne and seborrhoeic dermatitis.

(57) Abrégé : La présente invention concerne des composés de formule (I) suivante: pour laquelle n représente un nombre entier compris entre 1 et 15, m représente 0, 1, 2 ou 3, et R représente la chaîne hydrocarbonée d'un acide gras polyinsaturé choisi parmi les oméga 3 et les oméga 6, ainsi que des compositions pharmaceutiques ou cosmétiques les contenant, leur procédé de préparation et leur utilisation, notamment dans le traitement de l'acné et de la dermatite séborrhéique.

**POLYUNSATURATED FATTY ACID AND DIOL ESTER AS AN ANTI-
ACNE AGENT**

The present invention relates to esters of an
5 alkanediol and a polyunsaturated fatty acid, more
particularly an omega-3 or omega-6 fatty acid, as well
as to pharmaceutical and cosmetic compositions
containing same, to a method for preparing same and to
the use of same, in particular to treat acne or
10 seborrheic dermatitis.

Alkanediols are compounds used in numerous fields
such as cosmetics and agri-foods. Their use as a
preservative, by virtue of their bacteriostatic
properties, can be cited in particular. Thus,
15 alkanediols constitute a means to control fungal and
bacterial colonization and help protect many cosmetic
or agri-food products (Faergemann J, Fredriksson T.
Sabouraudia: 1980; 18, 287-293). These diols have a
broad spectrum of activity and are in particular
20 effective with respect to species of fungi and Gram-
positive bacteria (Harb NA, Toama MA. Drug Cosmet Ind:
1976; 118, 40). Moreover, the near absence of acquired
resistance in microorganisms enables alkanediols to be
important tools in the development of anti-resistance
25 strategies, in particular with respect to

Staphylococcus aureus (Faergemann J, Hedner T, Larsson P: 2005; 85, 203-205; WO 2004/112765). Finally, their very good tolerance enables them to be used frequently and at doses exceeding several percent.

5 In particular, 1,2-alkanediols have bacteriostatic activities and are widely used as preservatives (JP-A-51091327) or in the treatment of pathologies such as acne in which the microbial component plays a key role in etiology (US 6123953). Other applications of 1,2-
10 alkanediols are also described, such as protective properties with respect to body odors by virtue of their antiseptic (US 5516510; WO 2003/000220) or antifungal (WO 2003/069994) effect. Similarly, combinations of 1,2-alkanediols with other compounds
15 are described wherein the result is a synergistic antimicrobial effect. Thus, in this context, combinations to control microorganisms at the origin of body odors (US 2005/228032) or microorganisms involved in the formation of acne lesions (US 2007/265352, EP 20 1598064) have been claimed.

Polyunsaturated fatty acids (PUFAs) are divided into two categories: omega-3 (ω -3) and omega-6 (ω -6). Besides their metabolic effects, they are able to modify the expression of genes coding for intracellular 25 proteins. Such gene effects of PUFAs seem to be carried out via nuclear receptors called PPARs (peroxisome proliferator-activated receptors). PPARs belong to the family of nuclear steroid hormone receptors. They form heterodimers with the retinoid X receptor (RXR) of 30 retinoic acid and modulate gene expression. Thus, ω -3 PUFAs would be negative regulators of the inflammatory response by inhibiting the NF- κ B activation pathway via the induction of the expression of $I\kappa B\alpha$, which is the major inhibitor of the NF- κ B pathway (Ren J and Chung 35 SH. J Agric Food Chem. 2007 55:5073-80). Moreover, ω -3

PUFAs have an inhibiting action on the synthesis of arachidonic acid to the benefit of the synthesis of docosahexaenoic and eicosapentaenoic acids (Calder PC. *Lipids*: 2001; 36, 1007-24).

5 During acne, excess sebum in the follicular infundibulum represents a favorable environment for colonization by *Propionibacterium acnes* (*P. acnes*). A correlation can thus be established between the degree of colonization by *P. acnes* of the pilosebaceous canal
10 and the appearance of a microcomedo. Moreover, it has been shown that this colonization is greater in subjects with acne compared to healthy subjects (Brown S, Shalita A. *Acne vulgaris. Lancet* 1998; 351: 1871-6).

15 *P. acnes*, via receptors of the innate immune system, induce the production of NF- κ B-dependent proinflammatory cytokines such as IL-8. These mediators then influence in particular the migration of polynuclear neutrophils toward the site of inflammation, where their mission is to kill bacteria.
20 This inflammatory response is normal and necessary for the elimination of the pathogen in the infected tissue. However, excessive and uncontrolled activation leads to inflammatory acne lesions. Thus, it has been shown that IL-8 level is correlated to the number of neutrophils
25 mobilized in the inflammatory acne lesion (Abd El All HS et al. *Diagn. Pathol.* 2007; 2: 4).

30 Bacterial colonization in acne patients is most often associated with the appearance of inflammatory acne lesions: for example, a greater number of polymnuclear neutrophils and higher levels of IL-8 are found within the highly-colonized follicular canals compared to the lowly-colonized follicular canals of subjects without acne. The levels of these inflammatory markers appear correlated with bacterial load. But many
35 questions remain unanswered such as the cause of

colonization and the series of steps leading to lesion formation. In any event, the role of bacterial colonization as a factor in the progression of the disease is proven.

5 The current treatment for minor to moderate or inflammatory acne corresponds to a topical application of antibacterial active agents acting against colonization in particular by *P. acnes* in combination with anti-inflammatories (Shalita A., J. Eur. Acad. 10 Dermatol. Venereol. 2001; 15: 43).

Treatments are generally initiated after the appearance of a certain number of inflammatory acne lesions.

15 One of the major problems of anti-acne therapy is to find an adapted treatment, which is to say one proportional to the severity of the acne, that is begun as soon as possible, which is to say as of the initial colonization, against the development of inflammatory acne lesions.

20 The Inventors thus discovered in a surprising way that esters of an alkanediol and a polyunsaturated fatty acid, and more particularly an omega-3 or omega-6 polyunsaturated fatty acid, have an antibacterial and anti-inflammatory action as of the initial colonization 25 by *P. acnes* in the follicular canal, wherein this action is in addition proportional to the colonization.

Indeed, it turned out that alkanediol and PUFA esters are recognized and cleaved specifically by the bacterial (*P. acnes*) lipase, thus enabling, by cleavage 30 of the ester bond, the release of the two active agents with complementary activities, namely the antibacterial diol, capable of controlling colonization by *P. acnes*, and the anti-inflammatory PUFA, which blocks the recruitment of neutrophils and thus the inflammatory 35 cascade characteristic of acne. The release of these


two active agents thus induces an adapted response, which is to say one proportional to the colonization by *P. acnes*, as of the initial colonization and thus blocks the development of this pathology responsible for the appearance of inflammatory acne lesions. In addition, since *P. acnes* bacteria are present in subjects who do not have acne lesions, these esters also make it possible to prevent aggravation of the acne lesion by acting as of the formation of the comedo and by inhibiting the inflammatory cascade characteristic of acne.

Such esters have already been described in the literature (WO 98/18751; Sugiura et al., J. Biol. Chem. 1999, 274(5), 2794-2801) but not for their biological properties.

The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.

Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification (including the claims) they are to be interpreted as specifying the presence of the stated features, integers, steps or components, but not precluding the presence of one or more other features, integers, steps or components, or group thereof.

Thus, the present invention relates to a compound of the following general formula (I):




wherein:

- n is an integer between 1 and 15, preferably between 1 and 10,
- m is 0, 1, 2 or 3, and

- R is the hydrocarbon chain of a polyunsaturated fatty acid selected from omega-3 and omega-6 polyunsaturated fatty acids.

In another aspect, the present invention relates to a

5 compound of the following general formula (I):




wherein:

- n is an integer between 1 and 15,
- m is 0, 1, 2 or 3, and
- R is the hydrocarbon chain of a polyunsaturated fatty acid selected from omega-3 and omega-6 polyunsaturated fatty acids.

In the context of the present invention, "polyunsaturated fatty acid" refers to a linear carboxylic acid (R_1CO_2H) comprising from 10 to 28, preferably from 16 to 24, more preferably from 18 to 22, carbon atoms (including the carbon atom of the carboxylic acid function) and comprising at least 2,

preferably 2 to 6, C=C double bonds, wherein said double bonds preferably have a *cis* configuration.


In the context of the present invention, "hydrocarbon chain of a polyunsaturated fatty acid" refers to the hydrocarbon chain (R1) linked to the acid function of the polyunsaturated fatty acid (R1CO₂H). R1 thus represents a linear hydrocarbon chain comprising from 9 to 27, preferably from 15 to 23, more preferably from 17 to 21, carbon atoms and comprising at least 2, preferably 2 to 6, C=C double bonds, wherein said double bonds preferably have a *cis* configuration. Thus, in the case of the linoleic acid of the following formula:



15 the hydrocarbon chain considered is the following chain:




In the context of the present invention, "omega-3 fatty acid" refers to a polyunsaturated fatty acid, such as defined above, wherein the first double bond of the chain corresponds to the third carbon-carbon bond counting from the end opposite to the carboxylic acid function, as is illustrated in the case of the α -linolenic acid below:



Said omega-3 fatty acids can be in particular α -linolenic acid, stearidonic acid, eicosatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, 30 tetracosapentaenoic acid and tetracosahexaenoic acid, and preferably it is α -linolenic acid or stearidonic acid, which have anti-inflammatory properties.

In the context of the present invention, "omega-6 fatty acid" refers to a polyunsaturated fatty acid, such as defined above, wherein the first double bond of the chain corresponds to the sixth carbon-carbon bond counting from the end opposite to the carboxylic acid function, as is illustrated in the case of the linoleic acid below:



Said omega-6 fatty acids can be in particular linoleic acid, γ -linolenic acid, eicosadienoic acid, dihomo- γ -linolenic acid, arachidonic acid, docosatetraenoic acid, docosapentaenoic acid, adrenic acid and calendic acid, and preferably it is linoleic acid, which has sebum control properties.


In particular, n can be 1, 2, 3, 4 or 5, preferably 5. Advantageously, $n \geq 3$ and preferably $n \geq 5$.

Advantageously, m is 0 or 1.

Advantageously, $n+m \geq 3$ and preferably $n+m \geq 5$.

Advantageously, the hydrocarbon chain comes from a polyunsaturated fatty acid selected from α -linolenic acid, stearidonic acid, eicosatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, tetracosapentaenoic acid, tetracosahexaenoic acid, linoleic acid, γ -linolenic acid, eicosadienoic acid, dihomo- γ -linolenic acid, arachidonic acid, docosatetraenoic acid, docosapentaenoic acid, adrenic acid and calendic acid. Preferably, the polyunsaturated fatty acid will be selected from α -linolenic acid, stearidonic acid and linoleic acid, more preferably from α -linolenic acid and linoleic acid.

In particular, the compounds of the invention can be selected from the following molecules:



The present invention further relates to a compound of the formula (I) as defined above for the use of same as a drug, in particular intended to treat acne or seborrheic dermatitis.

10 The present invention further relates to the use of a compound of the formula (I) as defined above for the manufacture of a drug, in particular intended to treat acne or seborrheic dermatitis.

15 The present invention further relates to a method for treating acne or seborrheic dermatitis comprising the administration of an effective quantity of a compound of the formula (I) as defined above to a person in need thereof.

20 The present invention further relates to a pharmaceutical or cosmetic composition comprising at least one compound of the formula (I) as defined above in combination with at least one pharmaceutically or cosmetically acceptable excipient, adapted in particular to percutaneous administration.

25 In the present invention, "pharmaceutically or cosmetically acceptable" refers to that which is useful in the preparation of a pharmaceutical or cosmetic

composition and is generally safe, non-toxic and neither biologically nor otherwise undesirable and is acceptable for therapeutic or cosmetic use, in particular by topical application.

5 The pharmaceutical or cosmetic compositions according to the invention can be provided in the forms commonly used for topical application, which is to say in particular lotions, foams, gels, dispersions, emulsions, shampoos, sprays, serums, masks, body milks 10 or creams, with excipients that enable in particular cutaneous penetration in order to improve the properties and the accessibility of the active principle. Advantageously, said compositions are in the form of a cream.

15 Said compositions generally contain, in addition to the one or more compounds according to the present invention, a physiologically acceptable medium, in general water-based or solvent-based, for example based on alcohols, ethers or glycols. Said compositions can 20 also contain surfactants, sequestrants, preservatives, stabilizers, emulsifiers, thickeners, gellants, humectants, emollients, trace elements, essential oils, fragrances, colorants, mattifiers, chemical or mineral filters, moisturizers or thermal waters, etc.


25 Said compositions can further contain other active principles leading to a complementary or possibly synergistic effect.

Advantageously, the compositions according to the present invention will comprise from 0.01% to 10% by 30 weight, preferably from 0.1% to 1% by weight, of one or more compounds of the formula (I) compared to the total weight of the composition.

Said compositions are more particularly intended to treat acne or seborrheic dermatitis.

The present invention further relates to a method for the cosmetic treatment of acne or seborrheic dermatitis comprising the application on the skin of a cosmetic composition such as defined above.

5 The present invention further relates to a method for preparing a compound of the formula (I) as defined above by coupling a polyunsaturated fatty acid selected from omega-3 and omega-6 fatty acids, whose carboxylic acid function is in free or activated form, and a diol 10 of the following formula (II):



wherein n is an integer between 1 and 15, preferably between 1 and 10, and m is 0, 1, 2 or 3.

15 In particular, n can be 1, 2, 3, 4 or 5, preferably 5. Advantageously, $n \geq 3$ and preferably $n \geq 5$.

Advantageously, m is 0 or 1.

Advantageously, $n+m \geq 3$ and preferably $n+m \geq 5$.

20 In the context of the present invention, "free form" means that the carboxylic acid function of the PUFA is not protected and is thus a CO_2H group. The PUFA is thus of form $\text{R}_1\text{CO}_2\text{H}$ such as previously defined.

25 In the context of the present invention, "activated form" refers to a carboxylic acid function that is modified so as to make it more active with respect to nucleophiles. Said activated forms are well known to those persons skilled in the art and can be in particular an acid chloride (COCl). The activated PUFA in the form of an acid chloride thus has the formula R_1COCl .

30 According to a first particular embodiment of the invention, the polyunsaturated fatty acid is used in its free acid form. In this case, the coupling reaction will be carried out in the presence of a coupling agent

such as diisopropylcarbodiimide (DIC), dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), carbonyldimidazole (CDI), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 5 hexafluorophosphate (HBTU), 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) or 0-(7-azobenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU), optionally combined with a coupling auxiliary such as N-hydroxysuccinimide (NHS), N-10 hydroxybenzotriazole (HOBT), 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazole (HOOBt), 1-hydroxy-7-azabenzotriazole (HOAt), dimethylaminopyridine (DMAP) or N-hydroxysulfosuccinimide (Sulfo-NHS). Advantageously, the coupling will be carried out in the presence of a carbodiimide (in particular DIC, DCC or 15 EDC) and dimethylaminopyridine. Preferably, the coupling will be carried out in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride or diisopropylcarbodiimide and dimethylaminopyridine.

According to a second particular embodiment of the 20 invention, the polyunsaturated fatty acid is used in its activated form, and more particularly in the form of an acid chloride. In this case, the coupling reaction will advantageously be carried out in the presence of pyridine and dimethylaminopyridine.

25 The present invention will be better understood in the light of the nonrestrictive examples which follow.

DESCRIPTION OF THE FIGURES:

Figure 1: Detection of *P. acnes* lipase (33 kDa) in 30 inflammatory acne lesions (M corresponds to size markers; A corresponds to inflammatory acne lesions; B corresponds to comedos with no inflammation).

5 Figure 2: Study of the hydrolysis of the esters of the invention by recombinant *P. acnes* lipase after 2 h of incubation. The light gray column represents the results obtained with 3-hydroxybutyl α -linolenate, the dark gray column represents the results obtained with 2-hydroxypentyl α -linolenate, the black column represents the results obtained with 2-hydroxyoctyl α -linolenate, the white column represents the results obtained with 3-hydroxynonyl α -linolenate and the 10 hatched column represents the results obtained with glyceryl trilinolenate.

15 Figure 3: Activity of PUFAs on the release of interleukin 8 by human HaCaT keratinocytes stimulated by PMA/A23187 (proinflammatory agents).

20 Figures 4A, 4B and 4C: Effects of PUFAs on the production of eicosanoids (CYCLO: cyclooxygenase metabolites, LIPOX: lipoxygenase metabolites, AA: arachidonic acid) during an inflammatory response induced by PMA/A23187. The white columns represent the 25 control (a reaction medium without PUFAs); the light gray columns correspond to the activity of 2.3 μ g/ml PUFA; the dark gray columns correspond to the activity of 11.5 μ g/ml PUFA; and the black columns correspond to the activity of 23 μ g/ml PUFA. Figure 4A corresponds to α -linolenic acid, figure 4B corresponds to stearidonic acid and figure 4C corresponds to linoleic acid.

ABBREVIATIONS USED:

APCI	Atmospheric-pressure chemical ionization
30 MIC	Minimum inhibitory concentration
DPM	Disintegrations per minute
ESI	Electrospray ionization
HPLC	High-performance liquid chromatography
NMR	Nuclear magnetic resonance
35 Rf	Ratio to front

MS Mass spectrum

CFU Colony-forming unit

EXAMPLE 1: Synthesis of compounds of the invention


5 1.1. General method A: from an unsaturated fatty acid

The unsaturated fatty acid is put into solution in 20 ml anhydrous CH_2Cl_2 under circulating N_2 . A carbodiimide (coupling agent) (1.1 eq) and dimethylaminopyridine (0.5 eq) are then added directly. 10 After stirring the medium at room temperature for 5-10 minutes, the diol (5 eq) is added. The medium is stirred vigorously for 18 hours, under N_2 , away from light. The organic phase is then extracted with CH_2Cl_2 and then washed with a saturated NaCl solution, dried 15 on MgSO_4 , filtered and concentrated.

The crude product is a yellow oil which is purified by open column chromatography using silica gel ($\varnothing: 22 \times 3.5 \text{ cm}$) and CHCl_3 as solvent.

20 The following three products were prepared according to method A with diisopropylcarbodiimide as coupling agent.

25 3-Hydroxybutyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
($\text{C}_{22}\text{H}_{38}\text{O}_3$) (3-hydroxybutyl α -linolenate)



Purification conditions: elution gradient: $\text{CHCl}_3/\text{AcOEt}$: 95/5 then $\text{CHCl}_3/\text{AcOEt}$: 9/1

Translucent oil (yield: 69%)

Rf (CHCl₃/AcOEt: 9/1) = 0.5

NMR (¹H, CDCl₃) δ (ppm): 0.98 (t, 3H, CH₃ (a)); 1.22 (d, 3H, CH₃ (v)); 1.31 (m, 8H, CH₂ (o, n, m, 1)); 1.6 (m, 2H, CH₂ (p)); 1.8 (m, 2H, CH₂ (t)); 2.1 (m, 4H, CH₂ (2k, b)); 2.3 (t, 2H, CH₂ (q)); 2.8 (m, 4H, CH₂ (h, e)); 3.85 (m, 1H, CH (u)); 4.1-4.3 (m, 2H, CH₂ (s)); 5.4 (m, 6H, CH (c, d, f, g, i, j)).


NMR (¹³C, CDCl₃) δ (ppm): 14.24 (CH₃ (a)); 20.46 (CH₂ (b)); 23.42 (CH₃ (v)); 25.01 (CH₂ (p)); 25.5 (CH₂ (e)); 25.59 (CH₂ (h)); 27.16 (CH₂ (k)); 29.06 (CH₂ (o, n)); 29.07 (CH₂ (m)); 29.53 (CH₂ (l)); 34.3 (CH₂ (q)); 38.1 (CH₂ (t)); 61.51 (CH₂ (s)); 64.89 (CH (u)); 127.08 (CH (c)); 127.6 (CH (j)); 128.22 (CH (f)); 128.26 (CH (g)); 130.22 (CH (i)); 131.93 (CH (d)); 174.2 (C=O (r)).

MS: ESI+ [M+H]⁺=351.2 (100%); [M+Na]⁺=373.3 (48%)

APCI+ [M+H]⁺=351.2 (calculated M=350.2)

2-Hydroxypentyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

(C₂₃H₄₀O₃) (2-hydroxypentyl α-linolenate)



Purification conditions: CHCl₃/AcOEt: 98/2

Translucent oil (yield: 45%)

Rf (CHCl₃/AcOEt: 97/3)=0.58


NMR (¹H, CDCl₃) δ (ppm): 1 (m, 6H, CH₃ (w, a)); 1.25 (m, 10H, CH₂ (o, n, m, l, v)); 1.5 (m, 4H, CH₂ (p, u)); 1.65 (m,

4H, CH_2 (b, k); 2.1 (m, 2H, CH_2 e); 2.4 (t, 2H, CH_2 q); 2.8 (m, 2H, CH_2 h); 3.9 (m, 1H, CH t); 4.1-4.3 (m, 2H, CH_2 s); 5.4 (m, 6H, CH d, d, f, g, i, j).

NMR (^{13}C , CDCl_3) δ (ppm): 14.2 (CH_3 a, w); 18.6 (CH_2 v, b); 25.5 (CH_2 p); 25.5 (CH_2 p); 27.16 (CH_2 e); 28.9 (CH_2 h); 29.1 (CH_2 k); 29.4 (CH_2 o, n); 29.5 (CH_2 m); 34.17 (CH_2 q); 35.41 (CH_2 u); 68.53 (CH t); 69.76 (CH_2 s); 128.22 (CH c); 129.58 (CH j); 130.22 (CH f); 130.81 (CH i); 131.93 (CH d); 174.05 ($\text{C}=\text{O}$ r).

MS: APCI+ $[\text{M}+\text{H}]^+ = 365.1$ (calculated $M=364.3$)

3-Hydroxynonyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
($\text{C}_{27}\text{H}_{48}\text{O}_3$) (3-hydroxynonyl α -linolenate)



15

Purification conditions: $\text{CHCl}_3/\text{AcOEt}$: 96/4

Translucent oil (yield 73%)

RF ($\text{CHCl}_3/\text{AcOEt}$: 97/3) = 0.64

NMR (^1H , CDCl_3) δ (ppm): 0.95 (m, 3H, CH_3 aa); 1 (m, 3H, CH_3 a); 1.4 (m, 16H, CH_2 o, n, m, l, w, x, y, z); 1.5 (m, 2H, CH_2 v); 1.6-1.8 (m, 4H, CH_2 p, t); 2 (m, 4H, CH_2 k, b); 2.3 (t, 2H, CH_2 q); 2.8 (m, 4H, CH_2 h, e); 3.7 (m, 1H, CH u); 4.1-4.3 (m, 2H, CH_2 s); 5.4 (m, 6H, CH d, d, f, g, i, j).


NMR (^{13}C , CDCl_3) δ (ppm): 14 (CH_3 a, aa); 20.4 (CH_2 b); 22.5 (CH_2 z); 25.09 (CH_2 p); 25.26 (CH_2 w); 25.58

(CH₂ (e, h)) ; 27.17 (CH₂ (k)) ; 29.06-29.3 (CH₂ (x, o, n, m, l)) ; 31.7 (CH₂ (y)) ; 34.5 (CH₂ (q)) ; 37.45 (CH₂ (t)) ; 37.58 (CH₂ (v)) ; 61.59 (CH₂ (s)) ; 68.72 (CH (u)) ; 127.08 (CH (c)) ; 127.71 (CH (j)) ; 128.21 (CH (f)) ; 128.26 (CH (g)) ; 130.22 (CH (i)) ; 131.94 (CH (d)) ; 174.9 (C=O (r)).

5 MS: ESI+ [M+H]⁺=421.1 (100%) ; [M+Na]⁺=443.1 (92%)

The following product was prepared according to method A with 1-(3-dimethylaminopropyl)-3-10 ethylcarbodiimide hydrochloride as coupling agent.

2-Hydroxyoctyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
(C₂₆H₄₆O₃) (2-hydroxyoctyl α -linolenate)



15 Purification conditions: CHCl₃/AcOEt: 98/2
Translucent oil (yield 37%)
RF (CHCl₃/AcOEt: 98/2)=0.72
NMR (¹H, CDCl₃) δ (ppm): 0.88 (m, 3H, CH₃ (z)) ; 0.97 (t, 3H, CH₃ (a)) ; 1.31 (m, 16H, CH₂ (o, n, m, l, v, w, x, y)) ; 1.47 (m, 2H, CH₂ (u)) ; 1.65 (m, 2H, CH₂ (p)) ; 2.02 (m, 4H, CH₂ (b, k)) ; 2.4 (t, 2H, CH₂ (q)) ; 2.8 (m, 4H, CH₂ (e, h)) ; 3.9 (m, 1H, CH (t)) ; 4.1-4.3 (m, 2H, CH₂ (s)) ; 5.4 (m, 6H, CH (c, d, f, g, i, j)).
20 NMR (¹³C, CDCl₃) δ (ppm): 14.2 (CH₃ (a, w)) ; 18.6 (CH₂ (v, b)) ; 22.7 (CH₂ (y)) ; 25.5 (CH₂ (p)) ; 25.5 (CH₂ (p)) ; 27.16 (25 b)) ; 25.5 (CH₂ (p)) ; 27.16

(CH₂ (e)); 28.9 (CH₂ (h)); 29.1 (CH₂ (k)); 29.4 (CH₂ (o, n));
 29.5 (CH₂ (m)); 29.9 (CH₂ (w)); 31.7 (CH₂ (x)); 34.17 (CH₂
 (q)); 35.41 (CH₂ (u)); 68.53 (CH (t)); 69.76 (CH₂ (s));
 128.22 (CH (c)); 129.58 (CH (j)); 130.22 (CH (f) CH (g));
 5 130.81 (CH (i)); 131.93 (CH (d)); 174.05 (C=O (r)).

MS: APCI+ [M+H]⁺=407.3 (calculated M=406.34)

1.2. General method B: from a polyunsaturated fatty acid chloride


10 Linoleoyl chloride (6.7x10⁻³ mol) and dimethylaminopyridine (DMAP) (0.1 eq) are added, under circulating nitrogen, to a solution of diol (5 eq) in pyridine (20 ml). After vigorous stirring for 18 hours under N₂, at room temperature and away from light, the 15 reaction medium is reduced dry.

The organic phase is then extracted with AcOEt and then washed with H₂O and NH₄⁺Cl⁻, dried on MgSO₄, filtered and concentrated.

20 The crude product is a brown oil which is purified by open column chromatography using silica gel (Ø: 22x3.5 cm) and CHCl₃ as solvent.

The following product was prepared according to method B with pentylene glycol as the diol.

25 2-Hydroxypentyl (9Z,12Z)-octadeca-9,12-dienoate
 (C₂₃H₄₂O₃) (2-hydroxypentyl linoleate)



Purification conditions: $\text{CHCl}_3/\text{AcOEt}$: 98/2

Translucent oil

Rf ($\text{CHCl}_3/\text{AcOEt}$: 98/2) = 0.54

5 **NMR** (^1H , CDCl_3) δ (ppm): 0.9 (m, 6H, CH_3 (a, w)) 1.3 (m, 16H, CH_2 (o, n, m, l, b, c, d, v)); 1.45 (m, 2H, CH_2 (u)); 1.65 (m, 2H, CH_2 (p)); 2 (m, 4H, CH_2 (k, e)); 2.3 (t, 2H, CH_2 (q)); 2.8 (m, 2H, CH_2 (h)); 3.8 (m, 1H, CH (t)); 4.1-4.3 (m, 2H, CH_2 (s)); 5.4 (m, 4H, CH (f, g, i, j)).

10 **NMR** (^{13}C , CDCl_3) δ (ppm): 14.2 (CH_3 (a, w)); 18.6 (CH_2 (v)); 22.6 (CH_2 (b)); 25 (CH_2 (p)); 25.6 (CH_2 (h)); 27.2 (CH_2 (e, n)); 29 (CH_2 (o)); 29.1 (CH_2 (n)); 29.3 (CH_2 (d)); 29.4 (CH_2 (m)); 29.6 (CH_2 (l)); 31.4 (CH_2 (c)); 34.1 (CH_2 (q)); 36.2 (CH_2 (u)); 69 (CH_2 (s)); 70 (CH (t)); 127.78 (CH (g)); 127.91 (CH (i)); 129.94 (CH (f)); 130.22 (CH (j)); 174.05 (C=O (r)).

15 **MS**: **ESI+** $[\text{M}+\text{H}]^+$ = 367.3 (100%); $[\text{M}+\text{Na}]^+$ = 389.3 (80%)

EXAMPLE 2: Composition according to the invention

20 A formulation according to the invention, in cream form, with the following composition (the quantities are given in weight percentages compared to the total weight of the composition):

Quantity	Compound	Function
3	Glycerin	Humectant
0.1	Disodium EDTA*	Sequestrant

0.35	Phenoxyethanol	Preservative
1	Polyacrylate-13; Polyisobutene; Polysorbate 20; water (mixture sold under the name Sepiplus® 400 by SEPPIC)	Gellant and stabilizer
4	Glyceryl stearate; PEG-100 stearate (mixture sold under the name Simulsol® 165 by SEPPIC)	Emulsifier
1	Cetyl alcohol	Consistency factor
5	Cyclopentasiloxane	Emollient
3	Glyceryl tri-2-ethylhexanoate	Emollient
2	Dicaprylyl carbonate	Emollient
1	Diol and PUFA ester according to the invention	Anti-acne agent
0.27	Chlorphenesin	Preservative
2	Polymethyl methacrylate	Mattifying powder
0.1	Fragrance	Fragrance

*EDTA: ethylenediaminetetraacetic acid

EXAMPLE 3: Results of biological tests

3.1. Study of the action of *P. acnes* lipase on the compounds of the invention

First, it was shown by Western blot that the *P. acnes* lipase is strongly induced in the inflammatory lesions of subjects with acne compared to samples taken from healthy subjects (see figure 1).

Second, the action of recombinant *P. acnes* lipase on the compounds of the invention was studied as described below.

The enzymatic reaction was carried out by incubating the substrate at the desired concentration (500 µM) in TRIS buffer (left at room temperature for


1 h before the tests began) and then initiated the reaction by adding the enzyme and incubating at 37 °C. The tests are carried out in 2 ml amber glass vials. A control is carried out by not adding the enzyme in 5 order to evaluate the possible spontaneous hydrolysis of the substrate in the buffer. A 10 µl sample is taken at each desired time during the reaction and then frozen to quench the reaction. The linolenic acid released is then derivatized with anthryldiazomethane 10 (ADAM) which forms a fluorescent complex with the fatty acid. The product formed is separated by HPLC and then quantified using a standard range of commercial linolenic acid derivatized under the same conditions.

15 As shown in figure 2, the compounds of the invention give rise to a hydrolysis reaction in the presence of *P. acnes*, since the formation of α-linolenic acid is observed.

20 Thus, hydrolysis of the compounds of the invention by *P. acnes* releases both the diol and the PUFA. Expression of the lipase is thus a necessary condition to observe the cleavage of compounds of the invention and thus to obtain a therapeutic effect. In addition, 25 since the *P. acnes* lipase is essentially present in subjects with acne, as shown in figure 1, the compounds of the invention should enable an adapted response for each person.

3.2. Study of the antibacterial activity of the diols obtained after hydrolysis of the compounds of the invention

30 Said diols are of the following general formula (II):



wherein n is an integer between 0 and 15 and m is 0, 1, 2 or 3.

Tests were carried out with eight microbial strains using the dilution method described below.

Minimum inhibitory concentrations (MICs) are determined using a micromethod in liquid medium.

5 Successive 1/2 dilutions of the test products in culture medium (Trypcase Soy Broth) are carried out in 96-well microplates in a final volume of 0.1 ml. The wells are inoculated with 0.01 ml of the bacterial suspensions titrated at roughly 1×10^7 CFU/ml. The 10 microplates are incubated in optimal growth conditions and the MIC is read visually.

Table 1 below presents the results obtained with various diols. The columns labeled "BS" represent the bacteriostatic activity and the columns labeled "BC" 15 represent the bactericidal activity of the diols (1% corresponds to a concentration of 10 mg/ml).

Table I

Bacterium	1,3-Butanediol		1,2-Pentanediol		1,2-Octanediol		1,3-Nonanediol	
	BS	BC	BS	BC	BS	BC	BS	BC
<i>Staphylococcus aureus</i>	20%	>20%	20%	20%	0.312%	0.312%	0.312%	0.312%
<i>Staphylococcus epidermidis</i>	10%	20%	10%	10%	0.312%	0.312%	0.312%	0.312%
<i>P. acnes</i>	10%	20%	5%	20%	0.312%	0.312%	0.156%	0.312%
<i>Pseudomonas aeruginosa</i>	10%	20%	5%	10%	0.312%	0.312%	0.625%	0.625%
<i>Escherichia coli</i>	10%	20%	5%-10%	20%	0.156%	0.156%	0.156%	0.625%
<i>Candida albicans</i>	10%	10%	5%	5%	0.156%	0.312%	0.156%	0.156%
<i>Aspergillus niger</i>	10%	>20%	5%	20%	0.156%	0.625%	0.078%	0.625%
<i>M. furfur</i>	10%	20%	5%	10%	0.156%	0.312%	0.156%	0.312%

20 The antibacterial effect observed is consistent with the literature: namely, the activity is in relation to the length of the diol chain (Frankenfeld JW, Mohan RR, Squibb RL. J Agric Food Chem. 1975; 23: 418-425). Thus, 1,3-nonanediol and 1,2-octanediol are 25 bacteriostatic and bactericidal (Gram-positive, Gram-negative, fungal) at concentrations ranging from 6.25 mg/ml to 0.78 mg/ml. It should be noted that the

nonane derivative appears to have the most marked activity for the *P. acnes* strain with in particular a bacteriostatic and bactericidal effect found at 1.56 mg/ml and 3.12 mg/ml, respectively.

5 3.3. Study of the kinetics of the antibacterial activity of 1,2-octanediol

10 The kinetics of the antibacterial activity of 1,2-octanediol were studied by evaluating the lethality of the bacteria over time by counting residual colony-forming units (CFUs) after contact of the test solution with the bacterial suspension.

15 The bacterial strains used are: *Staphylococcus aureus* ATCC6538 and *Propionibacterium acnes* ATCC6919. The culture medium used for *Staphylococcus aureus* ATCC6538 is Trypcase Soy Agar whereas the culture medium used for *Propionibacterium acnes* ATCC6919 is Schaedler agar. Stock solutions containing 1% and 0.5% 1,2-octanediol are prepared extemporaneously in 1% Polysorbate 20 (qsp WFI) and then adjusted to pH 7 with 20 0.1 N NaOH solution.

25 A volume of 5 ml of each stock solution is inoculated with 50 μ l bacterial suspension titrated at roughly 1×10^8 CFU/ml.

30 After each time of contact (contact times tested: 5 min, 15 min, 30 min and 60 min), residual bacteria are counted by taking a 1 ml aliquot neutralized by 9 ml Trypcase Soy Broth and 10% Polysorbate 80.

35 Counting is carried out by adding 1 ml neutralized mixture and four 1/10 serial dilutions to the corresponding agar plates.

40 The agar plates are incubated at $36^\circ\text{C} \pm 1^\circ\text{C}$ in aerobic atmosphere for *S. aureus* and anaerobic atmosphere for *P. acnes* (Generbag anaer, Biomerieux) for 72 hours and then the CFUs are counted.

45 Table 2 below presents the results obtained.

Table 2

		<i>Staphylococcus aureus</i> Log R				<i>Propionibacterium acnes</i> Log R			
Concentration	pH	5 min	15 min	30 min	60 min	5 min	15 min	30 min	60 min
1%	7	>5.3	>5.3	>5.3	>5.3	>5	>5	>5	>5
0.5%	7	0.4	0.1	0.2	0.5	0.2	0.7	1.8	3
Negative control: 1% Polysorbate 20 excipient	6.5	0	0	0	0.1	0	0	0.2	0.3

- with R meaning "reduction". It refers to the ratio between the number of inoculated bacteria and the number of residual bacteria after contact of the test solution with the bacterial suspension.

The bactericidal action of the octanediol was examined on two bacterial species (*P. acnes*, *S. aureus*) at the two following concentrations of 0.5% and 1%. At physiological pH and at the lowest concentration (0.5%), a decrease greater than 99.9% of the population of *P. acnes* in particular is observed after one hour of contact.

15 3.4. Study of the anti-inflammatory activity of PUFAs obtained after hydrolysis of the compounds of the invention

The anti-inflammatory potential of the PUFAs was tested on human keratinocytes (HaCaT) stimulated by PMA/A23187. The results obtained are presented in figures 3, 4A, 4B and 4C.

20 The changes induced by these PUFAs are evaluated on the production of eicosanoids and an inflammatory cytokine, interleukin 8, during an inflammatory process triggered by PMA/A23187.

Study of IL-8 secretion (figure 3):

HaCaT cells are incubated on 96-well plates for 24 h in the presence of PUFAs, rinsed and then stimulated by PMA/A23187. The supernatants are recovered after 6 h of stimulation and IL-8 is quantified using the OptEIA™ ELISA kit (BD Pharmingen).

Study of arachidonic acid (AA) metabolism (figures 4A, 4B, 4C):

HaCaT keratinocytes were incubated in 24-well plates in the presence of 1 μ Ci [3 H]AA for 18 hours under an atmosphere of 5% CO₂. To test the capacity of PUFAs to modulate the inflammatory response of keratinocytes, [3 H]-labeled HaCaT cells are pretreated with PUFAs for 24 hours, rinsed and then stimulated by 500 nM PMA and 1 μ M A23187 for 5 hours. [3 H]AA and metabolites released by the HaCaT cells in the culture medium are extracted by column chromatography. The eluate is evaporated under N₂. The dry residue is taken up in methanol and deposited on thin-layer silica plates activated beforehand for 1 hour at 100 °C. The developing solvent is the organic phase of the mixture ethyl acetate/water/isooctane/acetic acid (110:100:50:20, v/v). [3 H]AA and metabolites (6-keto-prostaglandin F_{1 α} , 6k-PGF_{1 α} ; prostaglandin (PG) F α E2D₂; thromboxane (TX) B₂, leukotrienes (LT) B₄, C₄, D₄) are identified by a Berthold TLC scanner.

Thus, figure 3 shows the activity of certain PUFAs on the release of interleukin 8 (IL-8) by HaCaT human keratinocytes stimulated by PMA/A23187. An inhibitory effect on the IL-8 secretion of stimulated keratinocytes is clearly shown for γ -linolenic acid and particularly for α -linolenic acid.

Similarly, pre-incubation of keratinocytes with a PUFA such as α -linolenic acid, stearidonic acid or linoleic acid significantly inhibits the release of arachidonic acid and also the release of cyclooxygenated and lipoxygenated metabolites of the inflammatory cascade (figures 4A, 4B and 4C).


Thus, all of the results obtained confirm the anti-inflammatory activity of ω -3 or ω -6

polyunsaturated fatty acids and in particular α -linolenic acid.

The compounds according to the invention can thus be used to treat acne. Since the etiological pattern of 5 seborrheic dermatitis has similarities with that of acne, the compounds of the invention can potentially also be used to treat seborrheic dermatitis. Indeed, the microorganism at the origin of the inflammatory response in the context of this pathology, *Malassezia*, 10 secretes lipases (DeAngelis YM et al. J Invest Dermatol. 2007; 127: 2138-46) on the scalp which can also be used to release the two active agents, the alkanediol with antifungal properties and the PUFA such as α -linolenic acid with anti-inflammatory properties. 15 Moreover, certain fatty acids such as linoleic acid are activators of nuclear PPAR α receptors, which exert a marked sebum control effect (Downie MM et al. Br J Dermatol. 2004; 151: 766-75). Thus, diol-linoleic acid conjugates can be used in particular to limit seborrhea 20 in various indications such as acne and seborrheic dermatitis.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of the following general formula (I):



5 wherein:

- n is an integer between 1 and 15,
- m is 0, 1, 2 or 3, and
- R is the hydrocarbon chain of a polyunsaturated fatty acid selected from omega-3 and omega-6 polyunsaturated fatty acids.

10 2. The compound according to claim 1, wherein n is between 1 and 10.


15 3. The compound according to either of claims 1 and 2, wherein n is 1, 2, 3, 4 or 5.

20 4. The compound according to any one of claims 1 to 3, wherein m is 0 or 1.

25 5. The compound according to any one of claims 1 to 4, wherein the polyunsaturated fatty acid is selected from α -linolenic acid, stearidonic acid, eicosatrienoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, tetracosapentaenoic acid, tetracosahexaenoic acid, linoleic acid, γ -linolenic acid, eicosadienoic acid, dihomo- γ -linolenic acid, arachidonic acid, docosatetraenoic acid, docosapentaenoic acid, adrenic acid and calendic acid.

30 6. The compound according to claim 5, wherein the polyunsaturated fatty acid is α -linolenic acid, stearidonic acid or linoleic acid.

7. The compound according to any one of claims 1 to 6, wherein it is selected from the following molecules:



8. The compound of the formula (I) according to any one of claims 1 to 7, for its use as a drug.

9. The compound according to claim 8, wherein the drug is intended to treat acne or seborrheic dermatitis.


10. A pharmaceutical or cosmetic composition comprising at least one compound of the formula (I) according to any one of claims 1 to 7 in combination with at least one pharmaceutically or cosmetically acceptable excipient.

11. The pharmaceutical or cosmetic composition according to claim 10, wherein said composition comprises 0.01% to 10% by weight, of the said one or more compounds of the formula (I) compared to the total weight of the composition.

12. The pharmaceutical or cosmetic composition according to claim 11, wherein the composition comprises 0.1% to 1% by weight of the said one or more compounds of the formula (I) compared to the total weight of the composition.

13. A method for the cosmetic treatment of acne or seborrheic dermatitis comprising the application on the skin of a cosmetic composition according to any one of claims 10 to 12.

5 14. A method for preparing a compound of the formula (I) according to any one of claims 1 to 7 by coupling a polyunsaturated fatty acid selected from omega-3 and omega-6 fatty acids, whose carboxylic acid function is in free or activated form, and a diol of the following formula (II):



wherein n is an integer between 1 and 15, and m is 0, 1, 2 or 3.

15 15. The method according to claim 14, wherein n is an integer between 1 and 10.

16. The method according to any one of claim 14 or claim 15, wherein m is 0 or 1.

20 17. The method according to any one of claims 14 to 16, wherein the coupling reaction is carried out from the polyunsaturated fatty acid, whose carboxylic acid function is in free form, in the presence of a coupling agent selected from the group consisting of diisopropylcarbodiimide, 25 dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, carbonyldiimidazole, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate or 0-(7-azobenzotriazol-1-30 yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, optionally combined with a coupling auxiliary selected from the group consisting of N-hydroxysuccinimide, N-hydroxybenzotriazole, 3,4-dihydro-3-hydroxy-4-oxo-1,2,3-benzotriazole, 1-hydroxy-7-azabenzotriazole, dimethylaminopyridine or N-35 hydroxysulfosuccinimide.

18. The method according to any one of claims 14 to 17, wherein the coupling agent is 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and the coupling auxiliary is dimethylaminopyridine.

5

19. The method according to any one of claims 14 to 16, wherein the coupling reaction is carried out from the polyunsaturated fatty acid, whose carboxylic acid function is activated in the form of an acid chloride.

10

20. The method according to claim 19, wherein the coupling reaction is carried out in the presence of pyridine and dimethylaminopyridine.

15

21. A compound of the formula (I), prepared by the method according to any one of claims 14 to 20.

20

22. A method for the treatment of acne or seborrheic dermatitis comprising administering a therapeutically effective amount of a cosmetic composition according to any one of claims 10 to 12.

25

23. A compound according to claim 1, substantially as hereinbefore described with reference to any one of the Examples and/or Figures.

Figure 1






Figure 2



2 / 3

Figure 3



3 / 3

Figure 4A




Figure 4B




Figure 4C

